ActivBiotics and Metaphore Complete Merger Creating Late-Stage Company Addressing Serious Infections and Inflammation

13-Jan-2006

ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. announced that stockholder approval of the previously announced merger has been received and the merger is now complete. The merger creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical candidates. In connection with the transaction, ActivBiotics has issued, and Metaphore stockholders have received, shares of ActivBiotics stock and Metaphore will become a wholly owned subsidiary of ActivBiotics.

The ActivBiotics Board has been increased to 11 members, adding significant late stage clinical development and commercial experience. The ActivBiotics management team, headed by Steven Gilman, Ph.D., President and Chief Executive Officer, will continue to run the combined company out of its headquarters in Lexington, MA.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances